Q-omics provides the consensus-scored TRAJ11 profile across patient tissues and cancer cell-line models. TRAJ11 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TRAJ11 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, TRAJ11 RNA expression shows 13,079 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, KIRC, and LSCC as cancer lineages where TRAJ11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ11 survival associations across molecular data types. TRAJ11 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ11 RNA expression–survival associations across cancer types. High TRAJ11 expression shows unfavorable associations in MESO, TGCT, LUSC and BLCA, but favorable associations in UCEC and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TRAJ11 RNA expression.
This table summarizes TRAJ11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ11 shows lower tumor expression in LUAD and higher tumor expression in KIRC. The KIRC box plot shows higher TRAJ11 RNA expression in tumor versus normal tissue (log2 FC = +0.210, t-test p = .002).
This table shows molecular features associated with TRAJ11 in patient tissues and cancer cell lines. In patient samples, TRAJ11 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
